Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.
Articles by Michele B. Kaufman, PharmD, BCGP
Secukinumab: The Real World Experience of PsA Patients
Secukinumab therapy proved safe and effective for psoriatic arthritis patients with multiple co-morbidities and long treatment histories, according to recent research…
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…
Upadacitinib + Methotrexate & Other csDMARDs in RA Patients
A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…
Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
Ixekizumab vs. Adalimumab for PsA: How Do They Compare?
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
Tanezumab’s Phase 3 Results for OA
In a recent study, tanezumab proved safe and effective in the treatment of knee and hip osteoarthritis…
Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes
In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…
FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 43
- Next Page »